Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.40 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 2/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | PYGM | P11217 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446639 | 0.92 | NR1H2 (0.47) | NR1H2NR1H3GCK | |
| SCHEMBL2446184 | 0.89 | NR1H2 (0.49) | NR1H2NR1H3 | |
| SCHEMBL2446313 | 0.84 | NR1H2 (0.40) | NR1H2NR1H3GCK | |
| SCHEMBL2446319 | 0.84 | NR1H2 (0.49) | NR1H2NR1H3 | |
| SCHEMBL3507434 | 0.83 | NR1H2 (0.58) | NR1H2NR1H3 | |
| SCHEMBL3510252 | 0.82 | KMO (0.49) | NR1H2NR1H3KMOMEN1KMT2A | |
| SCHEMBL3508619 | 0.81 | NR1H2 (0.51) | NR1H2NR1H3 | |
| SCHEMBL2449196 | 0.81 | NR1H2 (0.49) | NR1H2NR1H3 | |
| SCHEMBL3350743 | 0.80 | NR1H2 (0.46) | NR1H2NR1H3 | |
| SCHEMBL3506200 | 0.78 | NR1H2 (0.55) | NR1H2NR1H3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367801-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | Wyeth LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184786-A1 | Polar Quinazolines | NR1H3, NR1H2, NR1I3 | NR1H2 2/4885NR1H3 1/4885HAVCR2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.